Two-year outcomes of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation: The Triluminate pivotal trial

Alex Sticchi interviews Saibal Kar about the two-year results of the Triluminate pivotal trial, unveiled at ACC.25 in Chicago.

After revisiting the one-year findings and outlining the study design, Saibal Kar highlights key takeaways: at two years, TriClip therapy significantly reduced heart failure hospitalisations compared to medical therapy—despite crossover in the control group. Without these crossovers, the difference would be even greater.
Improvements in tricuspid regurgitation severity and quality of life were sustained in TriClip-treated patients, and the therapy remained safe through two years, even for those who crossed over.

Finally, control patients who experienced worsening symptoms benefitted from TriClip after crossover, showing improvements in TR.